The Service Line

Reimbursement: The FTC’s three year case against the Big Three PBMs is down to one holdout, and closing it out cost CVS Caremark 8.5 billion dollars

On July 14, 2026, the Federal Trade Commission finalized a settlement with CVS Health’s Caremark Rx and its group purchasing arm Zinc Health Services, resolving the agency’s administrative antitrust case alleging the PBM’s rebate driven formulary design artificially inflated insulin list prices. The order bars Caremark from disadvantaging low list price insulin on standard formularies, requires a standard rebate pass through option for plan sponsors, and locks in affordability programs capping members’ insulin costs. The FTC projects up to 8.5 billion dollars in patient savings over 10 years, plus another 4.5 billion dollars unlocked through point of sale pharmacy counter rebates. Caremark is the second of the Big Three to close its case, following Cigna’s Express Scripts on February 4. That leaves UnitedHealth’s Optum Rx as the last holdout. The commission pulled Optum’s case from adjudication on June 15 to review a proposed consent agreement that would resolve the claims against Optum “in their entirety,” but no final order has been announced as of this issue. For any group negotiating a PBM contract this quarter, the practical read is that delinked, cost plus, and rebate pass through structures are becoming the default terms at two of the three national PBMs, and will likely be the default at all three once Optum’s order is final. Confidence: High on the Caremark and Express Scripts terms already in force. Medium on Optum Rx’s final settlement timing. Sources: FTC press release on the Caremark settlement, FTC’s case docket for the Big Three insulin matter, supplemented by Fierce Healthcare on the Optum Rx proposed deal.

Enforcement: CVS’s long term care pharmacy unit is 11 days from a bankruptcy court hearing that closes out a 950 million dollar fraud verdict

Omnicare, the CVS Health long term care pharmacy subsidiary that dispenses to nursing home and assisted living residents, faces an August 12 bankruptcy court hearing on the 440 million dollar settlement it reached with the Department of Justice on July 1 to resolve a decade old False Claims Act case. A federal jury found in April 2025 that Omnicare submitted more than 3.3 million false claims for prescriptions dispensed without valid orders between 2010 and 2018, a verdict a judge later set at nearly 950 million dollars in damages and penalties. Under the deal, CVS pays 130 million dollars within 14 days of approval and the remaining 310 million dollars by March 15, 2028. The settlement is conditioned on the bankruptcy court approving both it and Omnicare’s underlying sale, and that sale is already further along than it was when this vertical last checked in: Judge Stacey Jernigan approved GenieRx Holding’s 250 million dollar purchase of Omnicare’s operating business in May, and no party has filed a formal objection to either the sale or the settlement ahead of the hearing. Both the settlement and the sale need court sign off by August 15. Operators in long term care and institutional pharmacy should treat this as the live template for how OIG’s standing dispensing without valid prescription theory gets prosecuted and priced. Confidence: High on the settlement terms and the sale approval; Medium on final court approval given the hearing has not yet occurred. Sources: CVS Health’s own release on the Omnicare GenieRx sale approval, supplemented by Healthcare Dive.

Who’s Buying: Warburg Pincus put a name and a structure on the 7 billion dollar PANTHERx Rare deal

A Warburg Pincus led investor group, partnered with the Abu Dhabi Investment Authority, formally agreed on July 13, 2026 to acquire a controlling interest in PANTHERx Rare, the largest independent rare disease specialty pharmacy, in a transaction valued above 7 billion dollars including debt. The sellers, Nautic Partners, General Atlantic, and the Vistria Group, will retain minority stakes alongside PANTHERx management rather than exit entirely, and the deal still needs customary closing conditions and regulatory clearance before it closes in the coming months. It lands three weeks after Peak Rock Capital closed its purchase of Asembia, the specialty pharmacy industry’s dominant hub, distribution, and data services layer, and about a year into Cigna’s Evernorth committing 100 million dollars to an AI powered specialty pharmacy program. The pattern holds: private equity keeps paying up for the infrastructure and access layer behind specialty drugs rather than the manufacturers themselves. Confidence: High on the deal terms and named parties; Medium on final close timing, which remains subject to regulatory approval. Source: Warburg Pincus’s own announcement of the PANTHERx Rare acquisition.

Clinical Policy: FDA’s window to permanently bar bulk GLP-1 compounding closed two days ago

The public comment period on FDA’s proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the section 503B Bulks List closed July 30, 2026 at 11:59pm ET, after the agency extended it once from an original May 1 deadline. If finalized, the rule would foreclose large scale outsourcing facilities from compounding those GLP-1s outside a declared shortage, closing the last legal large scale compounding pathway now that all three drugs carry resolved shortage status. FDA has not indicated a timeline for a final determination. For telehealth platforms and compounding pharmacies still selling compounded GLP-1s on the shortage exception’s legacy, this is the moment the regulatory runway actually ends, and prescribers steering patients toward compounded product should be planning for a hard stop rather than a gradual wind down. Confidence: High on the comment deadline; Low on final rule timing, since FDA has given no public signal. Source: Federal Register notice extending the comment period.

The Operator Metric: 96.5 percent

In the National Community Pharmacists Association’s most recent member survey, 96.5 percent of independent pharmacists said Medicare Part D reimbursement threatens the viability of their business, and 30.3 percent said they were considering closing within the year. That is not an abstract sentiment number. NCPA’s own pharmacy count shows the industry losing roughly one independent community pharmacy a day nationally, a trend a Michigan roundtable of independent owners was still describing in almost identical terms in late July, pointing to reimbursements that run below the cost of the drug on a meaningful share of claims. Layer on a worsening pharmacist and technician pipeline, pharmacy school enrollment is down more than 60 percent from its 2011 peak, and the operator math gets harder on both the revenue and the staffing line at once. If your specialty group or MSO depends on a retail or LTC pharmacy network for adherence and dispensing, this is the number that tells you whether that network is still there next year. Confidence: Medium, this is member survey and industry count data rather than an audited census, but it is the same directional read across every source that ran the numbers this year. Sources: NCPA’s January 2025 member survey findings, NCPA’s 2024 Digest release on the closure rate, supplemented by Crain’s Grand Rapids on Michigan pharmacy closures and Becker’s Hospital Review on the workforce pipeline.